Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus tislelizumab for CNS lymphoma
ACTRN12622000547741Phase 2Terminated
- Sponsor
- Monash University
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib and tislelizumab in central nervous system lymphoma, sponsored by Monash University. Primary endpoint: Overall response rate of combination therapy. Started Jun 2023; status: terminated.
02
Drugs
zanubrutinibtislelizumab
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on ACTRN12622000547741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000547741.